Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

PaperCitations, authors & open-access status

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 224 citations, 2020 year and bronze oa status.

224
Citations
2020
Year
bronze
OA Status

Related on ScholarIQ

Krishna M. Sundar
Author
The Lancet Respiratory Medicine
Journal
Respiratory and Cough-Related Research
Topic
Respiratory and Cough-Related Research
Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Topic
Pneumonia and Respiratory Infections
Topic
470M+ articles · free account